Published by Pept Research LLC. Send a documentation question or correction.
Eloralintide Research Timeline: Discovery to Phase 3
A dated guide to the main Eloralintide evidence sources and how to interpret development stages without confusing them with product approval.
The Eloralintide research timeline includes receptor investigation, published early clinical studies, and the Phase 3 ENLIGHTEN program. Research status checked October 31, 2026. Development information can change, so use the linked primary sources when checking a later update.
This timeline summarizes evidence types and study milestones. It does not provide clinical-use instructions or transfer clinical findings to independently supplied research materials.
Eloralintide research milestones at a glance
| Evidence stage | Source to review | Date and scope of the record |
|---|---|---|
| Discovery and receptor investigation | Discovery publication, PMID 41109426 | Published online October 16, 2025; experimental background for the compound |
| Phase 1 | Proof-of-concept study, PMID 41559929 | Published online January 20, 2026; the separate 12-week study |
| Phase 2 | Randomized trial, PMID 41207310 | Published online November 6, 2025; the 48-week study |
| Phase 3 | ENLIGHTEN-1 registry record, NCT07321886 | Last update posted September 22, 2026; recruiting, with no results posted when checked |
These entries are a reading map, not a claim that every study in the development program is listed here.
The table is ordered by evidence stage, not publication date. The 12-week Phase 1 report appeared after the Phase 2 publication; this does not reverse the sequence of the underlying experiments.
Discovery research: establish the experimental context
Begin by identifying the study material and the questions investigated. The discovery paper is the appropriate starting point for understanding why later researchers examined the molecule. For the receptor vocabulary behind this work, see Eloralintide mechanism and amylin receptors.
Keep publication dates separate from experiment dates. A paper may describe work performed years earlier, and a later publication date does not necessarily indicate a later stage of experimentation.
Phase 1: read the design before the headline
The published Phase 1 report describes a 12-week, randomized, placebo-controlled study examining safety, tolerability, pharmacokinetics, and pharmacodynamics. Its observations concern that study population and protocol.
When reviewing an early study, record the participant population, duration, comparison groups, and measured endpoints. Check which conclusions are directly supported and which are proposals for further investigation. Do not convert the study's methods into instructions for a commercial RUO product.
Phase 2: a different study, a separate evidence record
The 48-week Phase 2 publication reports a randomized, double-blind, placebo-controlled investigation enrolling 263 participants at 46 US research centers.
Retain the paper as a separate record from the Phase 1 report. Different populations, follow-up periods, and methods mean that a simple side-by-side headline comparison can miss important context. In a literature summary, clearly label whether a statement comes from the abstract, full results, or supplementary methods.
Phase 3: the ENLIGHTEN program
Lilly's ENLIGHTEN-1 listing identifies a Phase III study of Eloralintide in adults with obesity or overweight without type 2 diabetes. The registry identifier shown is NCT07321886.
The registry records an actual study start of February 6, 2026, and estimated completion in July 2030. These are different fields: the estimated completion date is a plan, not a completed event or a results publication. Use the dated registry record when reconciling a sponsor page's broader date range.
A trial listing describes a study; it should not be presented as a completed results paper. Check the phase, status, record update, and any results posting separately. Phase 3 development also should not be described as regulatory approval.
Keep each study in a separate evidence record
A milestone belongs to the study described by its source. Preserve the compound identity, study identifier, evidence type, and review date for each entry. Our Eloralintide research records guide explains source traceability and the distinction between literature records and material documentation.
For an ongoing research tracker, use separate columns for publications, registry updates, and sponsor announcements. Label planned and completed milestones explicitly so that an anticipated event remains identifiable as a plan.
A repeatable way to check future updates
- Open the original publication, registry, or sponsor release.
- Record its identifier and the date you checked it.
- Distinguish actual events from planned milestones.
- Note whether methods and results are available.
- Preserve previous entries when making a dated correction.
For the compound introduction, return to what Eloralintide is. For material-specific questions, consult the Eloralintide product listing and laboratory evaluation guide; neither substitutes for a pharmaceutical clinical-trial record.
For laboratory research use only. Not for human or animal consumption or administration.